AP-SA02

Armata Gets $3.7M DoW Funding, Total Hits $32.4M for Phage Therapy

Armata Gets $3.7M DoW Funding, Total Hits $32.4M for Phage Therapy

Los Angeles – September 24, 2026 -- Armata Pharmaceuticals has received an additional $3.7 million in non-dilutive funding from the U.S. Department of War, pushing cumulative government support for its lead bacteriophage candidate AP-SA02 to approximately $32.4 million.

New funds mark first Phase 3-specific allocation under existing DoW award

The $3.7 million tranche represents the first capital earmarked specifically for Phase 3 execution under a previously announced award, following $28.7 million already disbursed. The funding flows through the Medical Technology Enterprise Consortium and is managed by the Naval Medical Research Command's Naval Advanced Medical Development unit, with backing from the Defense Health Agency and Joint Warfighter Medical Research Program.

FDA Grants Breakthrough Therapy Status to Armata's AP-SA02 Phage Drug

FDA Grants Breakthrough Therapy Status to Armata's AP-SA02 Phage Drug

Los Angeles – September 17, 2026 -- The U.S. Food and Drug Administration has granted Breakthrough Therapy designation to Armata Pharmaceuticals' AP-SA02, an intravenous multi-phage candidate for complicated Staphylococcus aureus bacteremia, stacking the designation atop existing Fast Track and Qualified Infectious Disease Product status.